Innovative Produktion pharmazeutischer Proteine in Pflanzen

The release of the pharmaceutical product Elelyso showed that plantderived biopharmaceuticals can compete economically with products from conventional expression systems. Improvements are required in terms of automation, consistency and purification as well as quality control and regulatory compliance to ensure a successful commercialization of biopharmaceuticals from plants and plant cells. Here we discuss possible improvements and challenges, which will affect the development of the molecular farming approach.